Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Milestone Pharmaceuticals	Exicure	Clearside Biomedical	Calithera Biosciences	SCYNEXIS
Symbol	NASDAQ:MIST	NASDAQ:XCUR	NASDAQ:CLSD	NASDAQ:CALA	NASDAQ:SCYX
Price Information
Current Price	$5.63	$1.79	$2.70	$2.10	$7.21
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.4	1.5	1.3	1.8	1.4
Analysis Score	3.4	3.5	3.3	3.4	3.5
Community Score	2.6	3.0	2.7	2.8	2.8
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.8	0.0	1.7	0.8
Earnings & Valuation Score	0.0	0.0	0.6	1.3	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$14.60	$9.60	$6.33	$5.20	$30.29
% Upside from Price Target	159.33% upside	436.31% upside	134.57% upside	147.62% upside	320.05% upside
Trade Information
Market Cap	$168.03 million	$157.51 million	$155.46 million	$155.50 million	$148.75 million
Beta	4.2	2.21	1.42	1.77	2.16
Average Volume	97,830	572,836	605,405	1,451,276	574,455
Sales & Book Value
Annual Revenue	N/A	$1.30 million	$2.17 million	$22.25 million	$120,000.00
Price / Sales	N/A	121.16	71.64	6.99	1,239.58
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$4.69 per share	$0.94 per share	$0.25 per share	$2.24 per share	$1.32 per share
Price / Book	N/A	1.90	10.80	0.94	5.46
Profitability
Net Income	$-55,230,000.00	$-26,300,000.00	$-30,770,000.00	$-89,860,000.00	$-53,710,000.00
EPS	($3.50)	($0.46)	($0.81)	($1.90)	($8.10)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-127.52%	-144.47%	N/A	N/A
Return on Equity (ROE)	-58.89%	-24.26%	-153.41%	-66.64%	-330.82%
Return on Assets (ROA)	-55.37%	-19.41%	-65.29%	-56.60%	-64.53%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	0.05%	N/A	1.39%
Current Ratio	18.26%	6.22%	1.95%	7.07%	3.89%
Quick Ratio	18.27%	6.22%	1.95%	7.07%	3.89%
Ownership Information
Institutional Ownership Percentage	51.88%	44.15%	24.77%	73.99%	36.92%
Insider Ownership Percentage	4.16%	26.70%	13.10%	11.90%	4.06%
Miscellaneous
Employees	28	63	33	92	38
Shares Outstanding	29.85 million	87.99 million	57.58 million	74.05 million	20.63 million
Next Earnings Date	5/13/2021 (Estimated)	5/13/2021 (Estimated)	5/17/2021 (Confirmed)	5/6/2021 (Confirmed)	5/10/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Novel antifungal effective against vulvovaginal candidiasis in phase 3 trials - Healio healio.com - May 5 at 6:31 PM
	African Trypanosomiasis Treatment Market 2021 Is Rapidly Increasing Worldwide in Near Future \| Merck & Co Inc, Novartis AG, Sanofi, Scynexis Inc - Clark County Blog clarkcountyblog.com - May 3 at 2:50 PM
	SCYNEXIS Presents Data at 2021 ACOG Demonstrating the - GlobeNewswire globenewswire.com - April 30 at 12:44 PM
	SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections finance.yahoo.com - April 30 at 12:44 PM
	Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY) and SCYNEXIS (SCYX) - Smarter Analyst smarteranalyst.com - April 29 at 9:03 PM
	African Trypanosomiasis Treatment Market 2021 Is Rapidly Increasing Worldwide in Near Future \| Top Companies Analysis- Merck & Co Inc, Novartis AG, Sanofi, Scynexis Inc, etc. - Clark County Blog clarkcountyblog.com - April 25 at 2:19 PM
	SCYNEXIS to Present Two Ibrexafungerp (Brexafemmeᵀᴹ) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting - Yahoo Finance finance.yahoo.com - April 20 at 10:34 PM
	SCYNEXIS to Present Two Ibrexafungerp (Brexafemmeᵀᴹ) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting - GlobeNewswire globenewswire.com - April 20 at 12:33 PM
	SCYNEXIS to Present Two Ibrexafungerp (Brexafemmeᵀᴹ) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting finance.yahoo.com - April 20 at 12:33 PM
	Yeast Infection Market to Achieve Significant Growth in the Near Future – Northern Gwinnett News - Northern Gwinnett News (NGwinnett.com) ngwinnett.com - April 20 at 2:32 AM
	SCYNEXIS (NASDAQ:SCYX) Price Target Cut to $40.00 by Analysts at Aegis americanbankingnews.com - April 19 at 11:32 AM
	2021 Trending News: Ileal Sodium Bile Acid Cotransporter Market by Market Share, Vendors, Growth Rate, Analysis, Product Type, Revenue\| Albireo Pharma Inc, CJ HealthCare Corp, GlaxoSmithKline Plc, Scynexis Inc - Los Hijos de la Malinche loshijosdelamalinche.com - April 18 at 12:37 PM
	SCYNEXIS, Inc. (NASDAQ:SCYX) share price rebounds 45.67% from the lows – but can it keep going? marketingsentinel.com - April 17 at 2:51 PM
	SCYNEXIS, Inc. (NASDAQ:SCYX) Receives Average Recommendation of "Buy" from Brokerages americanbankingnews.com - April 14 at 3:20 AM
	SCYNEXIS (NASDAQ:SCYX) Has Debt But No Earnings; Should You Worry? - Yahoo Finance finance.yahoo.com - April 13 at 8:46 AM
	SCYNEXIS (NASDAQ:SCYX) Has Debt But No Earnings; Should You Worry? finance.yahoo.com - April 12 at 7:04 PM
	SCYNEXIS (NASDAQ:SCYX) Price Target Lowered to $40.00 at Aegis americanbankingnews.com - April 12 at 5:00 PM
	Scynexis: Q4 Earnings Snapshot - The Advocate stamfordadvocate.com - March 30 at 12:23 AM
	Scynexis: Q4 Earnings Snapshot timesunion.com - March 29 at 2:21 PM
	Global Acute Vulvovaginal Candidiasis Treatment Market to Surpass US$ 397.8 Million by 2027, Says Coherent Market Insights (CMI) - ACROFAN USA us.acrofan.com - March 29 at 9:20 AM
	SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - Yahoo Finance finance.yahoo.com - March 29 at 9:20 AM
	Scynexis: Q4 Earnings Snapshot - San Francisco Chronicle sfchronicle.com - March 29 at 9:20 AM
	SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update finance.yahoo.com - March 29 at 9:20 AM
	SCYNEXIS Stock Is Estimated To Be Significantly Overvalued finance.yahoo.com - March 29 at 4:18 AM
	SCYNEXIS Stock Is Estimated To Be Significantly Overvalued - GuruFocus.com gurufocus.com - March 28 at 10:50 PM

Date	Company	Brokerage	Action
3/11/2021	Milestone Pharmaceuticals	HC Wainwright	Initiated Coverage
7/29/2020	Milestone Pharmaceuticals	Oppenheimer	Upgrade
7/24/2020	Milestone Pharmaceuticals	Jefferies Financial Group	Upgrade
7/23/2020	Milestone Pharmaceuticals	Cowen	Boost Price Target
7/23/2020	Milestone Pharmaceuticals	Piper Sandler	Boost Price Target
6/4/2019	Milestone Pharmaceuticals	CIBC	Initiated Coverage
6/3/2019	Milestone Pharmaceuticals	Piper Jaffray Companies	Initiated Coverage
12/18/2020	Exicure	BMO Capital Markets	Initiated Coverage
9/17/2020	Exicure	Chardan Capital	Boost Price Target
6/4/2020	Exicure	Guggenheim	Reiterated Rating
6/4/2020	Exicure	LADENBURG THALM/SH SH	Reiterated Rating
5/3/2021	Clearside Biomedical	Wedbush	Reiterated Rating
11/11/2020	Clearside Biomedical	Needham & Company LLC	Reiterated Rating
6/4/2020	Clearside Biomedical	Janney Montgomery Scott	Reiterated Rating
5/13/2020	Clearside Biomedical	Roth Capital	Initiated Coverage
12/17/2019	Clearside Biomedical	JMP Securities	Reiterated Rating
8/13/2019	Clearside Biomedical	Laidlaw	Downgrade
1/5/2021	Calithera Biosciences	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target
1/5/2021	Calithera Biosciences	Smith Barney Citigroup	Lower Price Target
1/5/2021	Calithera Biosciences	SVB Leerink	Downgrade
6/2/2020	Calithera Biosciences	William Blair	Reiterated Rating
4/19/2021	SCYNEXIS	Aegis	Lower Price Target
2/17/2021	SCYNEXIS	Maxim Group	Boost Price Target
1/5/2021	SCYNEXIS	Cantor Fitzgerald	Initiated Coverage

(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources